The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 856-862

  Zhang, Xue Yan ^a   Dong, Qiang Gang ^a   Huang, Jin Su ^a   Huang, Ai Mi ^a   Shi, Chun Lei ^a   Jin, Bo ^a   Sha, Hui Fang ^a   Feng, Jiu Xian ^a   Geng, Qin ^a   Zhou, Jin ^a   Xu, Hui Li ^a   Han, Bao Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bmi 1; cancer stem cells; CCSP; lung adenocarcinoma; OCT4

Indexed keywords

BMI1 PROTEIN; CLARA CELL PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTEROGLOBIN; YOUNG ADULT;

EID: 78649637532     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21718     Document Type: Article

References (58)

1. Scagliotti GV, Parikh P, von Pawel J, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
2. Shiras A, Chettiar ST, Shepal V, et al.: Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 2007; 25: 1478-1489.
3. Rajasekhar VK, Dalerba P, Passegué E, et al.: The 5th International Society for Stem Cell Research (ISSCR) Annual Meeting, June 2007. Stem Cells 2008; 26: 292-298.
4. Mimeault M, Hauke R, Mehta PP, et al.: Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-1011.
5. Reya T, Morrison SJ, Clarke MF, et al.: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Reynolds SD, Giangreco A, Hong KU, et al.: Airway injury in lung disease pathophysiology: Selective depletion of airway stem and progenitor cell pools potentiates lung inflammation and alveolar dysfunction. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1256-L1265.
7. Giangreco A, Reynolds SD, Stripp BR,: Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 2002; 161: 173-182.
8. Kim CF, Jackson EL, Woolfenden AE, et al.: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835.
9. Kim CF,: Paving the road for lung stem cell biology: Bronchioalveolar stem cells and other putative distal lung stem cells. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1092-L1098.
10. Dovey JS, Zacharek SJ, Kim CF, et al.: Bmi-1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci USA 2008; 105: 11857-11862.
11. Yang Y, Iwanaga K, Raso MG, et al.: Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 2008; 3: e2220.
12. Karoubi G, Gugger M, Schmid R, et al.: OCT4 expression in human non-small cell lung cancer: Implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 2009; 8: 393-397.
13. Clarke MF, Dick JE, Dirks PB, et al.: Cancer stem cellsa - Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
14. International Stem Cell Initiative., Adewumi O, Aflatoonian B, Ahrlund-Richter L, et al.: Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007; 25: 803-816.
15. Kashyap V, Rezende NC, Scotland KB, et al.: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the Nanog, OCT4, and SOX2 pluripotency transcription factors with Polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 2009; 18: 1093-1108.
16. Yu J, Vodyanik MA, Smuga-Otto K, et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
17. Grinnell KL, Yang B, Eckert RL, et al.: De-differentiation of mouse interfollicular keratinocytes by the embryonic transcription factor Oct-4. J Invest Dermatol 2007; 127: 372-380.
18. Chen YC, Hsu HS, Chen YW, et al.: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008; 3: e2637.
19. Sotomayor P, Godoy A, Smith GJ, et al.: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69: 401-410.
20. Hochedlinger K, Yamada Y, Beard C, et al.: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121: 465-477.
21. Van Lohuizen M, Frasch M, Wientjens E, et al.: Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature 1991; 353: 353-355.
22. Haupt Y, Bath ML, Harris AW, et al.: Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993; 8: 3161-3164.
23. Jacobs JJ, Kieboom K, Marino S, et al.: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
24. Jacobs JJ, Scheijen B, Voncken JW, et al.: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
25. Sherr CJ,: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 10: 731-737.
26. Lowe SW, Sherr CJ,: Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83.
27. Glinsky GV, Berezovska O, Glinskii AB,: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
28. Vonlanthen S, Heighway J, Altermatt HJ, et al.: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84: 1372-1376.
29. Kim JH, Yoon SY, Jeong SH, et al.: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004; 13: 383-388.
30. Kim JH, Yoon SY, Kim CN, et al.: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/ p14ARF proteins. Cancer Lett 2004; 203: 217-224.
31. Van Leenders GJ, Dukers D, Hessels D, et al.: Polycomb-group oncogenes EZH2, Bmi-1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-463.
32. Mohty M, Yang AS, Szydlo RM, et al.: The Polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-383.
33. Van Galen JC, Muris JJ, Oudejans JJ, et al.: Expression of the Polycomb-group gene Bmi-1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 2007; 60: 167-172.
34. Groome PA, Bolejack V, Crowley JJ, et al.: The IASLC Lung Cancer Staging Project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705.
35. Croker AK, Allan AL,: Cancer stem cells: Implication for the progression and treatment of metastatic disease. J Cell Mol Med 2008; 12: 374-390.
36. Rawlins EL, Hogan BL,: Epithelial stem cells of the lung: Privileged few or opportunities for many? Development 2006; 133: 2455-2465.
37. Ji H, Ramsey MR, Hayes DN, et al.: LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-881.
38. Lapidot T, Sirard C, Vormoor J, et al.: A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
39. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identify-cation of tumorgenic breast cancer cells. Proc Notl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
40. Singh SK, Clarke ID, Terasaki M, et al.: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 582l-5828.
41. Dontu G, Al-Hajj M, Abdallah WM, et al.: Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36: S59-S72.
42. Schoenhals M, Kassambara A, De Vos J, et al.: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162.
43. Pesce M, Scholer HR,: Oct-4: Gatekeeper in the beginnings of mammalian development. Stem Cells 2001; 19: 271-278.
44. Nichols J, Zernike B, Anastassiadis K, et al.: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-391.
45. Gidekel S, Pizov G, Bergman Y, et al.: Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003; 4: 361-370.
46. Donovan PJ,: High Octane fuel powers the stem cell. Nat Genet 2001; 29: 246-247.
47. Boiani M, Eckardt S, Scholer HR, et al.: Oct4 distribution and level in mouse clones: Consequences for pluripotency. Genes Dev 2002; 16: 1209-1219.
48. Breuer RH, Snijders PJ, Smit EF, et al.: Increased expression of the EZH2 Polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004; 6: 736-743.
49. Breuer RH, Snijders PJ, Sutedja GT, et al.: Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the Polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 2005; 48: 299-306.
50. Mihara K, Chowdhury M, Nakaju N, et al.: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006; 107: 305-308.
51. Song LB, Zeng MS, Liao WT, et al.: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
52. Liu JH, Song LB, Zhang X, et al.: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008; 97: 267-272.
53. Dutton A, Woodman CB, Chukwuma MB, et al.: Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007; 109: 2597-2603.
54. Denlinger CE, Rundall BK, Jones DR,: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: The role of NF-kappaB. Semin Thorac Cardiovasc Surg 2004; 16: 28-39.
55. Wang H, Pan K, Zhang HK, et al.: Increased Polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 535-541.
56. Dimri GP, Martinez JL, Jacobs JJ, et al.: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002; 62: 4736-4745.
57. Cui H, Hu B, Li T, et al.: Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007; 170: 1370-1378.
58. Kang MK, Kim RH, Kim SJ, et al.: Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007; 96: 126-133.